• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Globus Medical (GMED) Showcases New Spine Products, Is The 19% Upside Still There?

    Simply Wall St·10/24/2026 23:31:15
    语音播报

    Product preview at NASS and why it matters for Globus Medical stock

    Globus Medical (GMED) is presenting its newest spine technologies to surgeons at the North American Spine Society meeting, highlighting the SCRIPT patient specific implant platform and the XLIF Prone Procedural Solution.

    Recent price action for Globus Medical has been mixed. The share price is up 10.07% over the past 30 days and 6.43% over 90 days, yet the year to date share price return is down 6.75%. At the same time, the 1 year total shareholder return of 30.70% and 3 year total shareholder return of 78.30% point to stronger momentum over a longer horizon as the market reacts to product updates like the NASS preview and other developments around the business.

    Spot opportunities in spinal and orthopedics alongside Globus Medical by scanning our curated list of 95 robotics and automation stocks, which are also targeting surgical workflow and precision hardware.

    Globus Medical has rewarded patient holders over the past year, yet the mixed year to date move leaves a straightforward question: Does the current setup still tilt the risk reward in favour of new buyers when you run the numbers?

    Most Popular Narrative: 19% Undervalued

    On the numbers, the most followed narrative sees Globus Medical worth $100.92 a share, compared with the recent $81.41 close. This view puts a lot of weight on how its robotics and broader musculoskeletal platform feed through to profitability and capital returns.

    Disciplined capital allocation, including use of roughly half of free cash flow for share repurchases, a debt free balance sheet with US$840.5 million of cash and securities, and early delivery of NuVasive and Nevro synergy and EPS accretion targets, supports the potential for higher EPS and cash flow per share.

    See why 21 investors see Globus Medical as 19% undervalued.

    Result: Fair Value of $100.92 (UNDERVALUED)

    Still, the story can break if Enabling Technologies and Nevro remain weak for a longer period or if hospital pricing and procedure volumes tighten further.

    Find out about the key risks to this Globus Medical narrative.

    Next Steps

    Sentiment around Globus Medical is optimistic, but the only view that really counts is yours. Move quickly, review the key numbers and stress test the 5 key rewards.

    Looking for more Globus Medical style investment ideas?

    If you stop with Globus Medical, you miss the bigger picture. Let the Simply Wall Street Screener surface other potential opportunities aligned with your approach.